Injecto Polymers IPO Details: Price, Dates & Financials

Injecto Polymers reports PAT margin 4.26% and EBITDA margin 10.13%.

The debt-to-equity ratio of Injecto Polymers is 2.61. A lower ratio generally means the company relies less on borrowed money.

The price-to-book value (P/BV) of Injecto Polymers IPO is 2.40.

ROE (return on equity) shows profit earned on shareholders' money, ROCE (return on capital employed) shows profit earned on all capital used in the business, and RONW (return on net worth) measures return on the company's net worth. Higher figures usually indicate more efficient use of capital.

Compare ROE, ROCE, margins and P/BV of Injecto Polymers with listed companies in the same sector, and check the peer comparison given in the offer document. Ratios are only one input — they do not predict listing gains.

We require these key ratios to evaluate the financial health, profitability, valuation, and overall performance of the Injecto Polymers IPO. They help investors understand how efficiently the company operates, how much debt it carries, and whether its shares are reasonably valued compared with its earnings and assets for that specific Injecto Polymers IPO. These ratios also help assess the Injecto Polymers IPOs ability to generate profits, manage financial obligations, and deliver sustainable growth, enabling investors to make a more informed Injecto Polymers IPO investment decision.

Investors should examine the Injecto Polymers IPO's revenue growth, profitability, debt levels, cash flow, and earnings per share (EPS). These indicators help assess the Injecto Polymers IPO's financial stability, growth potential, and investment risks before investing in the Injecto Polymers IPO.